# 2025年11月6日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 补救性无创通气用于治疗拔管后呼吸衰竭

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188988](https://pubmed.ncbi.nlm.nih.gov/41188988)
**期刊：** Critical care (London, England)
**PMID：** 41188988
**DOI：** 10.1186/s13054-025-05689-w

### 第一部分 原文与翻译

**英文原标题：** Use of rescue noninvasive ventilation for post-extubation respiratory failure.

**英文摘要原文：**
BACKGROUND: Robust evidence supports the use of preemptive non-invasive ventilation (NIV) after extubation in selected high-risk patient cohorts. In contrast, current guidelines discourage the use of NIV as a rescue therapy for respiratory failure that develops later after extubation, based on earlier studies indicating a potential increase in hospital mortality due to delayed reintubation. Nonetheless, NIV continues to be employed in this setting. We conducted a post-hoc analysis of a randomized trial to assess the clinical outcomes of rescue NIV for post-extubation respiratory failure.

METHODS: In this post-hoc analysis of a randomized trial comparing high-flow with Venturi mask oxygen in hypoxemic patients after extubation, we included those who developed post-extubation respiratory failure according to prespecified criteria; patients who received rescue NIV per physician's decision were compared to those who received direct re-intubation. Criteria for re-intubation during NIV were prespecified. Odds ratio after inverse probability of treatment weighting and posterior probabilities by Bayesian regression are reported.

RESULTS: Among 494 extubated patients, 147 developed respiratory failure while receiving oxygen therapy, occurring at a median of 37 h [IQR 13-85] after extubation: 83 (57%) were treated with rescue NIV and 64 (43%) received immediate re-intubation. The rate of NIV failure was 58%, without differences between patients with hypoxemic respiratory failure and those with hypercapnia and/or respiratory distress (60% vs. 56%, p = 0.82). In the weighted cohort, the use of rescue NIV, compared to direct re-intubation, was associated with lower intensive care unit mortality (adjusted odds ratio = 0.31 [95%CI: 0.12-0.82], p = 0.019) and similar hospital mortality (adjusted odds ratio = 1.01 [95%CI: 0.43-2.33], p = 0.99). The posterior probability that NIV reduced intensive care unit mortality was > 90% across all priors. The posterior probability that NIV did not increase hospital mortality was 44% under a noninformative prior, 47% under a skeptical prior, and 39% under a pessimistic prior.

CONCLUSION: Rescue NIV for post-extubation respiratory failure is associated with high failure rates; however, when applied with well-defined criteria for reintubation, it does not appear to be clearly associated with increases in hospital mortality. A randomized trial to re-evaluate the efficacy of rescue NIV for post-extubation respiratory failure is warranted.

CLINICAL TRIAL REGISTRATION: Registered at clinicaltrials.gov (NCT02107183) on April 8th, 2014.

**中文摘要译文：**
背景：强有力的证据支持对特定高危患者群体在拔管后进行预防性无创通气（NIV）。相比之下，基于早期研究指出延迟再插管可能导致院内死亡率增加，目前的指南不推荐将NIV作为一种补救疗法用于治疗拔管后后期发生的呼吸衰竭。尽管如此，NIV在该场景下仍被持续使用。我们进行了一项随机试验的事后分析，以评估补救性NIV用于治疗拔管后呼吸衰竭的临床结局。

方法：在这项比较拔管后低氧血症患者使用高流量氧疗与文丘里面罩氧疗的随机试验的事后分析中，我们纳入了根据预设标准发生拔管后呼吸衰竭的患者；我们将根据医生决策接受补救性NIV治疗的患者与直接接受再插管的患者进行了比较。NIV期间进行再插管的标准是预先设定的。报告了采用逆概率治疗加权后的比值比和通过贝叶斯回归计算的后验概率。

结果：在494名拔管患者中，147名在接受氧疗期间发生了呼吸衰竭，发生时间中位数为拔管后37小时 [IQR 13-85]：其中83名（57%）接受了补救性NIV治疗，64名（43%）接受了立即再插管。NIV的失败率为58%，在低氧性呼吸衰竭患者与高碳酸血症和/或呼吸窘迫患者之间无显著差异（60% vs. 56%, p = 0.82）。在加权队列中，与直接再插管相比，使用补救性NIV与更低的重症监护室死亡率相关（调整后比值比 = 0.31 [95%CI: 0.12-0.82], p = 0.019），而院内死亡率相似（调整后比值比 = 1.01 [95%CI: 0.43-2.33], p = 0.99）。在所有先验条件下，NIV降低重症监护室死亡率的后验概率均 > 90%。在无信息先验、怀疑性先验和悲观性先验条件下，NIV不增加院内死亡率的后验概率分别为44%、47%和39%。

结论：用于治疗拔管后呼吸衰竭的补救性NIV与高失败率相关；然而，当应用明确的再插管标准时，它似乎与院内死亡率的增加没有明确关联。有必要开展一项随机试验来重新评估补救性NIV治疗拔管后呼吸衰竭的有效性。

临床试验注册：于2014年4月8日在clinicaltrials.gov注册（NCT02107183）。

### 第二部分 AI 大师评价

本研究通过对一项随机试验的事后分析，旨在挑战当前不推荐使用补救性无创通气（NIV）治疗拔管后呼吸衰竭的临床指南。研究采用逆概率治疗加权和贝叶斯回归等高级统计方法，比较了接受补救性NIV与直接再插管患者的临床结局。其关键发现是，尽管补救性NIV失败率较高，但在设有明确再插管标准时，它与更低的ICU死亡率和相似的院内死亡率相关，这提示延迟再插管的风险可能被高估。这项研究的价值在于，它为重新审视补救性NIV在特定临床场景下的应用提供了重要证据，并强调了开展新的随机对照试验以验证这些发现的必要性。

---

## 2. VExUS评分：优化其在围手术期与重症监护管理中的应用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188936](https://pubmed.ncbi.nlm.nih.gov/41188936)
**期刊：** Critical care (London, England)
**PMID：** 41188936
**DOI：** 10.1186/s13054-025-05687-y

### 第一部分 原文与翻译

**英文原标题：** VExUS score: optimizing its use in perioperative and critical care management.

**英文摘要原文：**
The Venous Excess Ultrasound (VExUS) score has been developed to grade venous congestion and predict acute kidney injury in cardiac surgical setting by combining inferior vena cava diameter with hepatic, portal, and renal venous Doppler patterns. While initial studies demonstrated associations with acute kidney injury, subsequent non cardiac setting ICU studies yielded contradictory results, prompting reevaluation of what VExUS actually measures. Analysis of VExUS components reveals the score reflects complex interactions between cardiac function, filling pressures, and volume status rather than pure volume assessment. Each component-IVC diameter, hepatic vein flow, portal vein flow, and renal vein flow-is differently influenced by cardiac function and volume status. Observational studies demonstrate that patients with highest VExUS scores often have cardiogenic shock despite low fluid balance, while those with significant volume excess may have low scores when cardiac function is preserved. This evolving understanding necessitates a correction in clinical practice, returning to the original physiological framework where VExUS reflects the interaction of venous return and cardiac function rather than simple volume overload parameter.

**中文摘要译文：**
静脉超声过负荷（VExUS）评分旨在通过结合下腔静脉直径与肝、门静脉及肾静脉的多普勒血流模式，对心脏手术背景下的静脉淤血进行分级，并预测急性肾损伤。尽管早期研究证实其与急性肾损伤相关，但随后在非心脏手术背景的ICU研究中却得出了矛盾的结果，这促使我们重新评估VExUS评分的真实测量意义。对VExUS各组成部分的分析表明，该评分反映的是心功能、充盈压和容量状态之间复杂的相互作用，而非单纯的容量评估。其每个组成部分——下腔静脉直径、肝静脉血流、门静脉血流和肾静脉血流——都不同程度地受到心功能和容量状态的影响。观察性研究表明，VExUS评分最高的患者即便在液体平衡为负时也常伴有心源性休克，而那些容量显著超负荷的患者在心功能代偿良好时，其评分可能很低。这一不断深入的理解要求临床实践进行修正，回归其最初的生理学框架，即VExUS评分反映的是静脉回流与心功能的相互作用，而非一个简单的容量超负荷参数。

### 第二部分 AI 大师评价

该文献是一篇重要的观点性综述，旨在纠正临床实践中对VExUS评分的普遍误解。文章通过分析VExUS各组成部分的生理学意义，明确指出该评分并非单纯的容量状态指标，而是反映心功能与静脉回流相互作用的复杂评估工具。其核心价值在于提醒临床医生，应结合患者的心功能状态来解读VExUS评分，避免仅凭高分判断为容量过负荷，从而优化重症及围术期患者的血流动力学管理，这对精准治疗具有重要的指导意义。

---

## 3. 沙门氏菌致病岛1注射体重编程宿主细胞翻译以逃避炎症反应。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188240](https://pubmed.ncbi.nlm.nih.gov/41188240)
**期刊：** Nature communications
**PMID：** 41188240
**DOI：** 10.1038/s41467-025-64744-w

### 第一部分 原文与翻译

**英文原标题：** The Salmonella pathogenicity island 1 injectisome reprograms host cell translation to evade the inflammatory response.

**英文摘要原文：**
During bacterial infection both the host cell and its invader must rapidly divert resources to synthesize specific proteins. For the host, these factors may be needed for innate immune responses, including programmed cell death, and in the bacteria newly synthesized proteins may include survival factors that counteract host defences. Salmonella is an important bacterial pathogen that invades and multiplies within host cells. It is well established that epithelial cell invasion is dependent upon the Salmonella pathogenicity island 1 (SPI-1) type III injectisome, a biological needle that penetrates host cells and injects effectors that promote bacterial internalization. However, the importance of the SPI-1 injectisome in infection of professional phagocytes such as macrophages, the predominant host cell type supporting systemic infection, is less clear. Through time-resolved parallel transcriptomic and translatomic studies of macrophage infection, we reveal SPI-1 injectisome-dependent infection of macrophages triggers rapid translation of transcription factors, including Early Growth Response 1 (EGR1). Despite EGR1's short half-life, its swift synthesis, driven by untranslated regions of its mRNA, is sufficient to inhibit the transcription of pro-inflammatory genes; this restrains inflammation and macrophage death which would otherwise abort systemic infection. This demonstrates the importance of translational activation in host-pathogen dynamics during bacterial infection.

**中文摘要译文：**
在细菌感染期间，宿主细胞及其入侵者都必须迅速调动资源以合成特定的蛋白质。对宿主而言，这些因子可能用于先天性免疫反应，包括程序性细胞死亡；而在细菌中，新合成的蛋白质可能包括对抗宿主防御的存活因子。沙门氏菌是一种重要的细菌病原体，它在宿主细胞内入侵并增殖。一个公认的事实是，沙门氏菌对上皮细胞的入侵依赖于其致病岛1（SPI-1）的III型注射体——一种能够穿透宿主细胞并注入效应蛋白以促进细菌内化的生物针头。然而，SPI-1注射体在感染巨噬细胞等专业吞噬细胞（支持全身性感染的主要宿主细胞类型）中的重要性尚不明确。通过对巨噬细胞感染进行时间分辨的平行转录组学和翻译组学研究，我们揭示了依赖SPI-1注射体的巨噬细胞感染会触发转录因子（包括早期生长反应因子1, EGR1）的快速翻译。尽管EGR1的半衰期很短，但由其mRNA非翻译区驱动的快速合成足以抑制促炎基因的转录；这抑制了炎症和巨噬细胞死亡，否则这些反应将中止全身性感染。这证明了在细菌感染过程中，翻译激活在宿主-病原体相互作用动力学中的重要性。

### 第二部分 AI 大师评价

本研究旨在阐明沙门氏菌致病岛1（SPI-1）注射体在感染巨噬细胞过程中的作用机制。研究团队创新性地运用了时间分辨的平行转录组学和翻译组学技术，揭示了SPI-1注射体能迅速重编程宿主细胞的翻译机制，特异性地促进了转录因子EGR1的合成。这一关键发现表明，沙门氏菌通过在翻译层面精准调控宿主，巧妙地抑制了促炎基因的转录，从而逃避了宿主的免疫反应，为细菌的全身性感染创造了条件。该研究不仅深化了我们对宿主-病原体相互作用的理解，也为抗感染治疗提供了新的潜在靶点。

---

## 4. 人类免疫缺陷病毒（HIV）感染者的肺部感染

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41130280](https://pubmed.ncbi.nlm.nih.gov/41130280)
**期刊：** Seminars in respiratory and critical care medicine
**PMID：** 41130280
**DOI：** 10.1055/a-2725-7350

### 第一部分 原文与翻译

**英文原标题：** Pulmonary Infections in Patients with Human Immunodeficiency Virus Infection.

**英文摘要原文：**
Pulmonary infection is an important cause of hospitalization, morbidity, and mortality in people living with human immunodeficiency virus (HIV; PWH) infection, especially in those with significant immunosuppression. Pneumonia, including Pneumocystis jirovecii and Mycobacterium tuberculosis etiologies, continues to be the most frequent pulmonary infection in PWH. However, identifying the etiology of pulmonary infection in PWH is challenging because of the overlap in clinical features and the frequency of co-infection. This review focuses on the current scientific evidence regarding pulmonary infection in PWH, including its epidemiology, clinical presentation, diagnosis, and management.

**中文摘要译文：**
肺部感染是人类免疫缺陷病毒（HIV）感染者（PWH）住院、发病和死亡的重要原因，尤其是在那些存在显著免疫抑制的患者中。肺炎，包括由耶氏肺孢子菌和结核分枝杆菌引起的肺炎，仍然是PWH中最常见的肺部感染。然而，由于临床特征的重叠和合并感染的频繁发生，确定PWH肺部感染的病原学具有挑战性。本综述聚焦于当前关于PWH肺部感染的科学证据，包括其流行病学、临床表现、诊断和治疗。

### 第二部分 AI 大师评价

本文是一篇关于HIV感染者肺部感染的综述性文章，系统性地总结了该领域的流行病学、临床表现、诊断及管理策略。文章强调，肺部感染（尤其是耶氏肺孢子菌肺炎和结核）依然是免疫抑制患者发病与死亡的主要原因，且病原学诊断因临床表现重叠及合并感染而充满挑战。该综述为临床医生提供了关于此重要临床问题的最新知识框架和实用指导，对于优化患者管理、改善预后具有重要的参考价值。

---

## 5. 棘白菌素类与两性霉素B脂质体治疗氟康唑耐药血流感染的比较效果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41025647](https://pubmed.ncbi.nlm.nih.gov/41025647)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41025647
**DOI：** 10.1128/aac.00355-25

### 第一部分 原文与翻译

**英文原标题：** Comparative effectiveness of echinocandins and liposomal amphotericin B for fluconazole-resistant  bloodstream infections.

**英文摘要原文：**
Current therapeutic options for fluconazole-resistant (FLZR-CP) bloodstream infections (BSI) are limited to echinocandins and liposomal amphotericin B (L-AmB). To the best of our knowledge, no real-world comparative effectiveness studies have assessed these agents. This study aimed to compare the effectiveness of echinocandins and L-AmB for the treatment of FLZR-CP BSI. This retrospective, observational study was conducted in two hospitals in Italy between January 2018 and December 2022. Eligible patients were adults (≥18 years old) with microbiologically confirmed FLZR-CP BSI who received targeted therapy with either echinocandins or L-AmB. Patients were matched (2:1) based on age, Charlson comorbidity index, presence of sepsis or septic shock, time to appropriate antifungal therapy (≤48 hours or > 48 hours from diagnosis), and infection source. A total of 63 patients were included (42 in the echinocandin group and 21 in the L-AmB group). In Cox regression, targeted therapy with echinocandins was not associated with increased mortality (adjusted hazard ratio 1.40; 95% confidence interval [CI] 0.33-5.92,  = 0.645). An exploratory sensitivity analysis including patients who did not receive source control yielded consistent results ( = 0.491). Furthermore, in the multivariable regression analysis, echinocandin therapy was not associated with an increased risk of persistent fungemia (adjusted odds ratio 1.61: 95% CI 0.43-5.99,  = 0.476). Treatment with echinocandins and L-AmB resulted in similar 30-day mortality and persistent fungemia rates in patients with FLZR-CP BSI. These findings confirm that echinocandins are a viable treatment option for  BSI, even for patients with fluconazole-resistant strains.

**中文摘要译文：**
目前，氟康唑耐药血流感染（BSI）的治疗选择局限于棘白菌素类和两性霉素B脂质体（L-AmB）。据我们所知，尚无真实世界中的比较效果研究对这些药物进行评估。本研究旨在比较棘白菌素类和L-AmB治疗氟康唑耐药血流感染的有效性。这是一项在意大利两家医院开展的回顾性、观察性研究，研究时间为2018年1月至2022年12月。符合条件的患者为年龄≥18岁的成人，经微生物学确诊为氟康唑耐药血流感染，并接受了棘白菌素类或L-AmB的靶向治疗。研究人员根据年龄、Charlson合并症指数、是否存在脓毒症或感染性休克、接受适当抗真菌治疗的时间（诊断后≤48小时或>48小时）以及感染源，对患者进行了2:1匹配。共纳入63例患者（棘白菌素类组42例，L-AmB组21例）。在Cox回归分析中，接受棘白菌素类靶向治疗与死亡率增加不相关（调整后风险比为1.40；95%置信区间[CI]为0.33-5.92，P = 0.645）。一项纳入了未接受感染源控制患者的探索性敏感性分析得出了相似的结果（P = 0.491）。此外，在多变量回归分析中，棘白菌素类治疗与持续性真菌血症风险增加不相关（调整后比值比为1.61；95% CI为0.43-5.99，P = 0.476）。对于氟康唑耐药血流感染患者，棘白菌素类和L-AmB治疗的30天死亡率和持续性真菌血症发生率相似。这些发现证实，即使对于氟康唑耐药菌株感染的患者，棘白菌素类仍是治疗血流感染的可行选择。

### 第二部分 AI 大师评价

本研究通过一项回顾性匹配队列研究，直接解决了临床上一个重要且缺乏证据的难题：如何选择治疗氟康唑耐药血流感染的药物。研究严谨地比较了棘白菌素类与两性霉素B脂质体的疗效，关键发现两者在30天死亡率和持续性真菌血症方面效果相当。这项真实世界证据极具临床价值，它为临床医生在面对此类棘手感染时，使用通常更安全、更便捷的棘白菌素类药物提供了有力支持，确认了其作为一种可行治疗方案的地位。

---

## 6. 免疫功能低下患者持续性SARS-CoV-2病毒排毒≥8周的临床结局与病毒学动态：一项2020-2024年回顾性多中心队列研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41004259](https://pubmed.ncbi.nlm.nih.gov/41004259)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41004259
**DOI：** 10.1128/aac.00658-25

### 第一部分 原文与翻译

**英文原标题：** Immunocompromised patients with persistent SARS-CoV-2 viral shedding ≥8 weeks, clinical outcomes, and virological dynamics: a retrospective multicenter cohort study, 2020-2024.

**英文摘要原文：**
Immunocompromised patients (ICPs) infected with SARS-CoV-2 are at higher risk of severe illness. Some experience persistent viral shedding beyond eight weeks, which is associated with increased mortality and invasive fungal infections. However, data on the clinical profile, treatment impact, and standardized management for these patients remain limited. We conducted a retrospective cohort study at Groupe Hospitalier Paris Centre between March 1, 2020, and February 10, 2024. We assessed symptomatic ICPs with persistent SARS-CoV-2 shedding (>8 weeks), analyzing clinical progression, time to viral clearance, and emergence of resistance mutations in relation to treatment regimens. Fifty-three patients were included: 53% were solid organ transplant (SOT) recipients, 42% had hematological malignancies (HMs), and 5% had other immunosuppressive conditions. Severe infections occurred in 32%, 91% required hospitalization, and 17% ( = 9) presented invasive mold infections. SOT recipients achieved clinical cure faster than HM patients ( < 0.01). Patients treated with direct antivirals showed significantly faster viral clearance ( = 0.03) than those treated with monoclonal antibodies (mAbs) or convalescent plasma. No resistance mutations emerged against remdesivir or nirmatrelvir/ritonavir. However, 54% of viral strains showed initial or acquired spike protein resistance to mAbs. Direct antiviral therapies, particularly remdesivir and nirmatrelvir/ritonavir, appear safe and effective in promoting faster viral clearance and clinical recovery in ICPs with persistent symptomatic SARS-CoV-2 infection.

**中文摘要译文：**
感染SARS-CoV-2的免疫功能低下患者（ICPs）发展为重症的风险更高。部分患者会出现超过八周的持续性病毒排毒，这与死亡率和侵袭性真菌感染的增加有关。然而，关于这些患者的临床特征、治疗效果及标准化管理的数据仍然有限。我们于2020年3月1日至2024年2月10日期间，在巴黎中心大学医院集团（Groupe Hospitalier Paris Centre）进行了一项回顾性队列研究。我们评估了有症状且持续性SARS-CoV-2排毒（>8周）的ICPs，分析了其临床进展、病毒清除时间以及与治疗方案相关的耐药突变的出现情况。研究共纳入53名患者：其中53%为实体器官移植（SOT）受者，42%患有血液系统恶性肿瘤（HMs），5%存在其他免疫抑制状况。32%的患者发生了严重感染，91%需要住院治疗，17%（n = 9）出现了侵袭性霉菌感染。SOT受者比HM患者更快达到临床治愈（P < 0.01）。接受直接抗病毒药物治疗的患者比接受单克隆抗体（mAbs）或恢复期血浆治疗的患者显示出明显更快的病毒清除速度（P = 0.03）。未出现针对瑞德西韦或奈玛特韦/利托那韦的耐药突变。然而，54%的病毒株显示出对mAbs的初始或获得性刺突蛋白耐药。直接抗病毒疗法，特别是瑞德西韦和奈玛特韦/利托那韦，在促进持续性有症状SARS-CoV-2感染的ICPs实现更快的病毒清除和临床恢复方面，表现出安全性和有效性。

### 第二部分 AI 大师评价

本研究通过一项回顾性多中心队列研究，聚焦于持续排毒超过8周的免疫功能低下新冠患者这一特殊群体。其核心发现是，直接抗病毒药物（如瑞德西韦和奈玛特韦/利托那韦）在加速病毒清除方面显著优于单克隆抗体，且未引发耐药。该研究为这一高风险人群的临床管理提供了宝贵的循证依据，明确了直接抗病毒药物的治疗优势，对优化治疗方案、减少耐药风险具有重要的指导价值。

---

## 7. 一种锌螯合环状烷基多胺化合物在多重耐药耳念珠菌感染的小鼠模型中表现出高效性与安全性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41004200](https://pubmed.ncbi.nlm.nih.gov/41004200)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41004200
**DOI：** 10.1128/aac.00856-25

### 第一部分 原文与翻译

**英文原标题：** A zinc-chelating cyclic alkyl polyamine compound is efficient and safe in a murine model of multidrug-resistant  infection.

**英文摘要原文：**
 is an emerging multidrug-resistant fungal pathogen associated with severe nosocomial outbreaks and high mortality rates worldwide. The increasing incidence of antifungal resistance underscores the urgent need for agents with novel mechanisms of action. APC6 is a zinc-chelating cyclic alkyl polyamine compound that selectively disrupts zinc homeostasis in fungal cells. We have previously reported that APC6 has antifungal activity against  spp., including , and low cytotoxicity to human cells. In this study, we evaluated the  efficacy and safety of APC6 using a neutropenic murine model of disseminated  infection. APC6 significantly improved survival and reduced fungal burden in the liver, kidneys, and brain. At a therapeutic dose of 15 mg/kg, APC6 had similar or superior antifungal activity to that of amphotericin B. Histopathological analysis revealed a decreased number of fungal microabscesses in APC6-treated tissues. No significant adverse effects were observed following 28-day repeated intraperitoneal administration, and the Ames assay revealed no mutagenic activity. To our knowledge, this is the first study to demonstrate that a zinc-chelating compound can improve survival and reduce organ fungal burden in a mammalian model of drug-resistant  infection. These results highlight APC6 as a promising lead compound targeting fungal zinc homeostasis and support its further development as a novel antifungal agent.

**中文摘要译文：**
耳念珠菌是一种新兴的多重耐药真菌病原体，与全球范围内严重的医院内暴发和高死亡率相关。抗真菌药物耐药率的不断上升凸显了开发具有新作用机制药物的迫切需求。APC6是一种锌螯合环状烷基多胺化合物，能选择性地破坏真菌细胞内的锌稳态。我们先前曾报道，APC6对包括耳念珠菌在内的念珠菌属具有抗真菌活性，且对人体细胞的细胞毒性较低。本研究中，我们采用中性粒细胞减少的播散性耳念珠菌感染小鼠模型，评估了APC6的体内疗效与安全性。APC6显著提高了小鼠的存活率，并降低了肝、肾及脑部的真菌负荷。在15 mg/kg的治疗剂量下，APC6的抗真菌活性与两性霉素B相当或更优。组织病理学分析显示，经APC6治疗的组织中真菌微脓肿数量减少。连续28天腹腔注射后未观察到显著不良反应，且Ames试验显示其无致突变活性。据我们所知，这是首个证明锌螯合化合物能在耐药耳念珠菌感染的哺乳动物模型中提高存活率并降低器官真菌负荷的研究。这些结果凸显了APC6作为一种靶向真菌锌稳态的有前景的先导化合物，并支持其作为新型抗真菌药物的进一步开发。

### 第二部分 AI 大师评价

本研究旨在评估新型锌螯合化合物APC6在多重耐药耳念珠菌感染动物模型中的体内疗效与安全性。研究通过构建免疫抑制小鼠感染模型，发现APC6不仅能显著提高小鼠存活率、有效清除多器官的真菌负荷，其疗效媲美甚至优于临床药物两性霉素B，且展现出良好的安全性。此项工作首次在哺乳动物层面证实了靶向真菌锌稳态策略的可行性，为应对棘手的耐药真菌感染提供了一个极具潜力的候选药物和全新的治疗思路。

---

## 8. Epetraborole在结核分枝杆菌中空纤维系统模型中的药代动力学/药效动力学研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40980919](https://pubmed.ncbi.nlm.nih.gov/40980919)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 40980919
**DOI：** 10.1128/aac.00481-25

### 第一部分 原文与翻译

**英文原标题：** Epetraborole pharmacokinetics/pharmacodynamics in the hollow fiber system model of <Mycobacterium tuberculosis>.

**英文摘要原文：**
In the hollow fiber system model of tuberculosis (TB), the ratio of area under the concentration-time curve to MIC (AUC/MIC) of 327.1 was identified as the epetraborole optimal exposure target for <Mycobacterium tuberculosis> kill. Monte Carlo simulation experiments showed that even the intravenous dose of 1,500 mg/twice daily would fail in the majority of patients, and the dose needed for good efficacy for TB may likely not be safe for patients.

**中文摘要译文：**
在结核病（TB）中空纤维系统模型中，浓度-时间曲线下面积与最低抑菌浓度（AUC/MIC）的比值为327.1被确定为epetraborole杀灭结核分枝杆菌的最佳暴露目标。蒙特卡洛模拟实验表明，即使是1500毫克每日两次的静脉注射剂量，对大多数患者也可能无效，并且为达到良好抗结核疗效所需的剂量对患者而言可能并不安全。

### 第二部分 AI 大师评价

本研究利用先进的结核病中空纤维系统模型，旨在确定新型抗结核药物依珀硼罗（epetraborole）杀灭结核分枝杆菌的最佳药代动力学/药效动力学（PK/PD）指标。研究的关键发现是，虽然确定了AUC/MIC比值327.1为最佳暴露靶点，但蒙特卡洛模拟进一步揭示，即使采用高剂量静脉给药方案，也难以在多数患者中达到此疗效阈值。此研究的价值在于，通过前沿的体外模型与计算机模拟结合，前瞻性地评估了药物的临床应用潜力，其结论对epetraborole作为抗结核药物的开发提出了重大挑战，提示其有效剂量可能带来不可接受的安全性风险，为药物研发决策提供了关键的负面证据。

---

## 9. 比较不同硫酸粘菌素方案治疗神经重症监护患者碳青霉烯类耐药革兰氏阴性菌肺炎的回顾性队列研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40980916](https://pubmed.ncbi.nlm.nih.gov/40980916)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 40980916
**DOI：** 10.1128/aac.00644-25

### 第一部分 原文与翻译

**英文原标题：** Comparison of different colistin sulfate regimens for carbapenem-resistant gram-negative bacteria pneumonia in neurocritical care patients: a retrospective cohort study.

**英文摘要原文：**
Nosocomial infection caused by carbapenem-resistant gram-negative bacteria (CR-GNB) is a common problem in neurocritical care patients. Clinical evidence suggests that polymyxins have benefits for CR-GNB pneumonia. This study compared the efficacy and safety of different colistin sulfate regimens in CR-GNB pneumonia. Among 133 neurocritical care patients with CR-GNB pneumonia in the intensive care unit (ICU), 24 received nebulized colistin sulfate alone (NC group); 38 received intravenous colistin sulfate alone (IV group); and 71 received nebulized plus intravenous colistin sulfate (NCIV group). After inverse probability of treatment weighting (IPTW), clinical failure rates on days 7 and 14 were significantly higher in the IV group than in the NC group (38.3% vs. 20.5%,  = 0.017 and 32.1% vs. 15.3%,  = 0.004, respectively) and the NCIV group (38.3% vs. 24.7%,  = 0.023 and 32.1% vs. 14.2%,  = 0.015, respectively). Moreover, the IV group also reported a lower microbiological eradication rate on day 14 ( = 0.031) and longer ICU ( = 0.020) and hospital stays ( = 0.037) than the NCIV group. No significant difference in mortality risk and nephrotoxicity among the groups. In multivariable analysis, intravenous colistin sulfate was an independent factor associated with higher clinical failure on day 14 (adjusted odds ratio = 5.92, 95% CI = 1.14-30.84,  = 0.035). Our study suggested that nebulized colistin sulfate with concurrent intravenous administration may be an effective and safe option for CR-GNB pneumonia.

**中文摘要译文：**
由碳青霉烯类耐药革兰氏阴性菌（CR-GNB）引起的院内感染是神经重症监护患者中的一个常见问题。临床证据表明，多粘菌素类药物对CR-GNB肺炎有益。本研究旨在比较不同硫酸粘菌素方案治疗CR-GNB肺炎的有效性和安全性。在133名重症监护室（ICU）中患有CR-GNB肺炎的神经重症监护患者中，24名单独接受雾化吸入硫酸粘菌素治疗（NC组）；38名单独接受静脉注射硫酸粘菌素治疗（IV组）；71名接受雾化吸入联合静脉注射硫酸粘菌素治疗（NCIV组）。经过逆概率治疗加权（IPTW）分析后，IV组在第7天和第14天的临床失败率显著高于NC组（分别为38.3% vs. 20.5%, P = 0.017和32.1% vs. 15.3%, P = 0.004）和NCIV组（分别为38.3% vs. 24.7%, P = 0.023和32.1% vs. 14.2%, P = 0.015）。此外，与NCIV组相比，IV组在第14天的微生物清除率较低（P = 0.031），且ICU住院时间（P = 0.020）和总住院时间（P = 0.037）更长。各组间的死亡风险和肾毒性无显著差异。在多变量分析中，单独静脉注射硫酸粘菌素是导致第14天临床失败率较高的独立危险因素（调整后比值比 = 5.92, 95% CI = 1.14-30.84, P = 0.035）。我们的研究表明，雾化吸入联合静脉给予硫酸粘菌素可能是治疗CR-GNB肺炎的一种有效且安全的选择。

### 第二部分 AI 大师评价

本研究通过一项回顾性队列研究，聚焦于神经重症这一特殊患者群体，旨在比较雾化、静脉及联合使用硫酸粘菌素治疗耐药菌肺炎的优劣。研究方法上，采用逆概率治疗加权法（IPTW）减少了组间偏倚，增强了结论的可靠性。其核心发现——静脉联合雾化吸入方案在降低临床失败率和微生物清除方面优于单独静脉用药，且未增加肾毒性或死亡风险——为临床实践提供了重要的循证依据。尽管是回顾性研究，但该结论对优化危重患者的抗感染策略具有显著的指导价值，并提示了局部给药在肺部感染治疗中的潜力。

---

## 10. 在暴露前沿靶向耐药性：一项关于头孢洛扎/他唑巴坦持续输注的群体PK/PD蓝图

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40980909](https://pubmed.ncbi.nlm.nih.gov/40980909)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 40980909
**DOI：** 10.1128/aac.01042-25

### 第一部分 原文与翻译

**英文原标题：** Targeting  resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusion.

**英文摘要原文：**
Ceftolozane/tazobactam is a key antibiotic for  infections. Our objective was to determine whether continuous infusion (CI) of ceftolozane/tazobactam can achieve aggressive pharmacokinetic/pharmacodynamic (PK/PD) targets that suppress resistance and improve outcomes in severe  infections. A retrospective analysis of adult patients receiving CI ceftolozane/tazobactam and therapeutic drug monitoring (TDM) of both compounds was performed. Population PK/PD modeling identified the most accurate method for estimating ceftolozane/tazobactam clearance based on kidney function and Monte Carlo simulations investigated the relationship between various CI dosing regimens and aggressive PK/PD target attainment of ceftolozane/tazobactam. The 2021 non-race-based Chronic Kidney Disease Epidemiological Collaboration (CKD-EPI) equation with body surface area indexation provided the most reliable clearance estimates. Simulations showed that CI regimens of 4-6 g/2-3 g daily achieved optimal target attainment (≥90%) across all kidney function strata for MICs up to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint. Cumulative fraction of responses remained robust against key resistance phenotypes: MDR (12.6%; 83.8%), pan-beta-lactam-nonsusceptible (8.2%; 78.2%), and difficult-to-treat resistant (6.7%; 71.7%). Even among isolates with MIC >4 mg/L, aggressive target attainment was reached in 15%-40% of cases. This study suggests that CI ceftolozane/tazobactam, informed by TDM and optimized for aggressive PK/PD targets, offers a promising strategy to maximize efficacy and suppress resistance in severe  infections. These findings warrant prospective clinical trials of CI-based, exposure-guided therapy.

**中文摘要译文：**
头孢洛扎/他唑巴坦是治疗铜绿假单胞菌感染的关键抗生素。本研究旨在确定持续输注（CI）头孢洛扎/他唑巴坦能否达到旨在抑制耐药并改善重症铜绿假单胞菌感染预后的激进药代动力学/药效动力学（PK/PD）目标。我们对接受头孢洛扎/他唑巴坦持续输注并对两种药物成分进行治疗药物监测（TDM）的成年患者进行了一项回顾性分析。通过群体PK/PD建模，我们识别了基于肾功能估算头孢洛扎/他唑巴坦清除率的最准确方法，并利用蒙特卡洛模拟研究了不同持续输注给药方案与头孢洛扎/他唑巴坦激进PK/PD目标达成率之间的关系。结果显示，采用体表面积校正的2021年非种族慢性肾脏病流行病学合作组织（CKD-EPI）方程能提供最可靠的清除率估算值。模拟结果表明，对于MIC值达到欧洲抗菌药物敏感性测试委员会（EUCAST）折点水平的菌株，每日4-6克/2-3克的持续输注方案在所有肾功能分层中均能实现最优的目标达成率（≥90%）。该方案对关键耐药表型的累积目标达成率依然稳健，包括：多重耐药（MDR）菌株（12.6%；83.8%）、泛β-内酰胺类不敏感菌株（8.2%；78.2%）以及难治性耐药菌株（6.7%；71.7%）。即使是对于MIC >4 mg/L的分离株，仍有15%-40%的病例达到了激进的PK/PD目标。本研究表明，在治疗药物监测的指导下，针对激进PK/PD目标进行优化的头孢洛扎/他唑巴坦持续输注方案，为最大化疗效并抑制重症铜绿假单胞菌感染中的耐药性提供了一种有前景的策略。这些发现为开展基于持续输注的、以药物暴露为导向的治疗策略的前瞻性临床试验提供了依据。

### 第二部分 AI 大师评价

本研究精准地回应了临床上如何优化头孢洛扎/他唑巴坦给药以克服铜绿假单胞菌耐药性的迫切需求。研究团队巧妙地结合了回顾性临床数据、群体PK/PD建模和蒙特卡洛模拟，不仅验证了持续输注策略在达成激进PK/PD目标上的优越性，还为临床实践提供了具体的剂量参考和肾功能评估工具（2021 CKD-EPI方程）。其创新价值在于为个体化、基于暴露指导的抗感染治疗提供了强有力的循证依据，有望成为未来应对难治性细菌感染的重要参考蓝图，极具临床转化潜力。

---

## 11. 比较头孢洛扎/他唑巴坦与基于多粘菌素的方案早期治疗多重耐药铜绿假单胞菌（MDR-PSA）所致肺炎的效果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40965589](https://pubmed.ncbi.nlm.nih.gov/40965589)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 40965589
**DOI：** 10.1128/aac.00569-25

### 第一部分 原文与翻译

**英文原标题：** Comparison of early treatment with ceftolozane/tazobactam versus polymyxin-based therapy of pneumonia due to MDR Pseudomonas aeruginosa (PUMA).

**英文摘要原文：**
Ceftolozane/tazobactam and polymyxin-based regimens are frequently used to treat pneumonia caused by multi-drug-resistant Pseudomonas aeruginosa (MDR-PSA). However, comparative data on global clinical outcomes between these therapies are limited. A multi-centered observational study was performed using the PINC AI Healthcare Database (2016-2022). The study population included hospitalized patients ≥ 18 years who were diagnosed with pneumonia and had MDR-PSA (defined as non-susceptible to ≥1 agent in ≥3 antimicrobial categories) on a respiratory or blood culture, receipt of ceftolozane/tazobactam or a polymyxin-based regimen within 3 days of index MDR-PSA culture, receipt of ≥2 days of ceftolozane/tazobactam or a polymyxin-based regimen, and without a COVID-19 diagnosis. A Desirability of Outcome Ranking (DOOR) analysis was performed. Components of the DOOR included in-hospital mortality, discharge destination (home vs other), recurrent MDR-PSA pneumonia, receipt of any renal replacement therapy (RRT) post-index culture in RRT-naive patients, and 30-day pneumonia-related readmissions. In total, 186 patients met the study criteria (104 ceftolozane/tazobactam and 82 polymyxin). In the IPW-adjusted DOOR analysis, a ceftolozane/tazobactam-treated patient had a higher probability of a more favorable outcome (DOOR probability: 61.3%; 95% CI: 56.8%, 65.7%). In the DOOR partial credit analyses, a ceftolozane/tazobactam-treated patient had a higher probability of being discharged home alive with no undesirable outcomes than a polymyxin-treated patient (20.2% vs 9.8%, P = 0.04). This real-world evidence study of non-COVID-19 patients with MDR-PSA pneumonia suggests that patients treated with ceftolozane/tazobactam have a higher probability of a more favorable outcome compared with patients treated with a polymyxin-based regimen. Further large-scale studies with detailed dosing are needed to validate the findings.

**中文摘要译文：**
头孢洛扎/他唑巴坦和基于多粘菌素的治疗方案常用于治疗由多重耐药铜绿假单胞菌（MDR-PSA）引起的肺炎。然而，关于这两种疗法在总体临床结局方面的比较数据有限。本研究使用PINC AI医疗保健数据库（2016-2022年）进行了一项多中心观察性研究。研究人群包括年龄≥18岁的住院患者，这些患者被诊断为肺炎，并在呼吸道或血培养中检出MDR-PSA（定义为对≥3类抗菌药物中的≥1种药物不敏感），在首次MDR-PSA培养后的3天内接受了头孢洛扎/他唑巴坦或基于多粘菌素的方案治疗，接受了≥2天的头孢洛扎/他唑巴坦或基于多粘菌素的方案治疗，并且未诊断为COVID-19。研究进行了一项期望结局排序（DOOR）分析。DOOR的组成部分包括院内死亡率、出院去向（回家 vs 其他）、MDR-PSA肺炎复发、初次培养后未接受肾脏替代治疗（RRT）的患者接受任何RRT的情况，以及30天内因肺炎相关的再入院。总共有186名患者符合研究标准（104名接受头孢洛扎/他唑巴坦治疗，82名接受多粘菌素治疗）。在经逆概率加权（IPW）调整的DOOR分析中，接受头孢洛扎/他唑巴坦治疗的患者获得更有利结局的概率更高（DOOR概率：61.3%；95% CI：56.8%，65.7%）。在DOOR部分计分分析中，与接受多粘菌素治疗的患者相比，接受头孢洛扎/他唑巴坦治疗的患者在无不良事件下存活出院回家的概率更高（20.2% vs 9.8%，P = 0.04）。这项针对非COVID-19的MDR-PSA肺炎患者的真实世界证据研究表明，与接受基于多粘菌素方案治疗的患者相比，接受头孢洛扎/他唑巴坦治疗的患者获得更有利结局的概率更高。需要进一步开展包含详细给药信息的大规模研究来验证这些发现。

### 第二部分 AI 大师评价

本研究旨在通过一项多中心真实世界研究，比较头孢洛扎/他唑巴坦与多粘菌素方案在早期治疗多重耐药铜绿假单胞菌（MDR-PSA）肺炎中的临床效果。该研究创新性地采用了期望结局排序（DOOR）分析方法，综合评估了死亡率、出院去向及并发症等多个维度的临床结局。研究核心发现，与多粘菌素相比，头孢洛扎/他唑巴坦治疗的患者获得更有利临床结局的概率显著更高。这项研究为临床医生在处理MDR-PSA肺炎时提供了重要的循证依据，但也提示未来需要更大规模的研究来验证其结论。

---

## 12. 利用生理过程解析药物相互作用：BPaL方案的转录拆解分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40965512](https://pubmed.ncbi.nlm.nih.gov/40965512)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 40965512
**DOI：** 10.1128/aac.00492-25

### 第一部分 原文与翻译

**英文原标题：** Deconvoluting drug interactions using  physiologic processes: transcriptional disaggregation of the BPaL regimen .

**英文摘要原文：**
A key challenge in preclinical tuberculosis drug development is identifying optimal antibiotic combinations. Drug interactions are complex because one drug may affect  () physiology in a way that alters the activity of another drug. Conventional pharmacodynamic evaluation based on colony-forming units (CFU) does not provide information about this physiologic interaction because CFU enumerates bacteria but does not give information about the drug's effect on bacterial cellular processes. SEARCH-TB is a novel pharmacodynamic (PD) approach that uses targeted  transcriptional profiling to evaluate drug effects on  physiology. To evaluate SEARCH-TB's capacity to elucidate drug interactions, we deconstructed the BPaL (bedaquiline, pretomanid, and linezolid) regimen in the BALB/c high-dose aerosol mouse infection model, measuring the effect of 2-, 7-, and 14-day treatment with drugs in monotherapy, pairwise combinations, and as a three-drug combination. Monotherapy induced drug-specific  transcriptional responses by day 2 with continued evolution over 14 days. Bedaquiline dominated pairwise combinations with pretomanid and linezolid, whereas the pretomanid-linezolid combination induced a transcriptional profile intermediate between either drug. In the three-drug BPaL regimen, adding both pretomanid and linezolid to bedaquiline yielded a greater transcriptional response than expected, based on pairwise results. This work demonstrates that physiologic perturbations induced by a single drug may be modified in complex ways when drugs are combined. This establishes proof of concept that SEARCH-TB provides a highly granular readout of drug interactions  providing information distinct from CFU burden and suggesting a future where regimen selection is informed by  molecular measures of  physiology.

**中文摘要译文：**
临床前结核病药物开发的一个关键挑战是确定最佳的抗生素组合。药物相互作用是复杂的，因为一种药物可能通过影响细菌生理学的方式来改变另一种药物的活性。基于菌落形成单位（CFU）的传统药效学评价无法提供关于这种生理相互作用的信息，因为CFU只计算细菌数量，而不提供药物对细菌细胞过程影响的信息。SEARCH-TB是一种新颖的药效学（PD）方法，它利用靶向转录谱分析来评估药物对生理机能的影响。为了评估SEARCH-TB阐明药物相互作用的能力，我们在BALB/c高剂量气溶胶小鼠感染模型中解构了BPaL（贝达喹啉、普托马尼和利奈唑胺）方案，测量了单药治疗、两两组合以及三药联用方案在治疗2天、7天和14天时的效果。单药治疗在第2天就诱导了药物特异性的转录反应，并在14天内持续演变。在与普托马尼和利奈唑胺的两两组合中，贝达喹啉占据主导地位，而普托马尼-利奈唑胺组合则诱导了介于两种单药之间的转录谱。在BPaL三药方案中，与两两组合的结果相比，在贝达喹啉的基础上同时加入普托马尼和利奈唑胺，产生了超出预期的更强烈的转录反应。这项工作表明，单一药物引起的生理扰动在药物联用时可能会以复杂的方式被改变。这为SEARCH-TB能够提供药物相互作用的高度精细化读数建立了概念验证，该信息不同于菌落形成单位负荷，并预示了未来方案选择将由生理机能的分子测量指标来指导。

### 第二部分 AI 大师评价

本研究旨在验证一种名为SEARCH-TB的新型药效学方法，通过分析结核分枝杆菌的转录谱变化，来深入解析抗结核药物联合治疗中的相互作用机制。研究者以关键的BPaL方案为例，在小鼠模型中发现，该方法能揭示传统CFU计数无法捕捉的复杂生理学互动，例如贝达喹啉在两药联用中的主导效应，以及三药联用时产生的超预期的转录反应。这项工作的创新性在于提供了一个分子层面的、高分辨率的工具来评估和优化药物组合，超越了仅观察杀菌效果的传统模式，为未来基于分子生理学信息指导抗结核新方案的开发提供了概念验证和重要启示。

---

## 13. 甲氧苄啶-磺胺甲噁唑的群体药代动力学及基于蒙特卡洛模拟的给药方案优化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40899995](https://pubmed.ncbi.nlm.nih.gov/40899995)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 40899995
**DOI：** 10.1128/aac.00519-25

### 第一部分 原文与翻译

**英文原标题：** Population pharmacokinetics and Monte Carlo-based dosing optimization of trimethoprim-sulfamethoxazole.

**英文摘要原文：**
This study aimed to develop population pharmacokinetic (PopPK) models for intravenous sulfamethoxazole (SMX) and trimethoprim (TMP) to optimize dosing regimens for the treatment of  pneumonia using these models. A prospective study was conducted in 79 patients treated with intravenous trimethoprim-sulfamethoxazole. PopPK models were developed using nonlinear mixed-effect modeling to evaluate the effects of liver function, kidney function, and genetic polymorphisms ( and ) on pharmacokinetic parameters. Monte Carlo simulations were employed to identify the optimal dosing regimen. Pharmacokinetic analysis of SMX and TMP included 232 post-dose plasma concentrations from 79 adult patients. A one-compartment model with first-order elimination best described the data. Creatinine clearance (CrCL) was significantly correlated with the pharmacokinetic parameters of both SMX and TMP, while continuous renal replacement therapy significantly influenced only the SMX model. Liver function, , and  genotypes did not exhibit statistically significant effects on the models. Co-trimoxazole 50 mg/kg/day in a three-times-daily divided dose regimen is feasible for patients with CrCL of <15 mL/min. However, in patients with normal renal function, the guideline-recommended 90 mg/kg/day dose demonstrates a risk of supratherapeutic exposure. This study provides critical pharmacokinetic insights into SMX and TMP for patients, highlighting the necessity for dose adjustments in those with renal dysfunction. The currently recommended dosing regimens in clinical guidelines pose a risk of excessive drug exposure. Our study offers a more precise dosing strategy to optimize treatment efficacy and safety.

**中文摘要译文：**
本研究旨在建立静脉注射磺胺甲噁唑（SMX）和甲氧苄啶（TMP）的群体药代动力学（PopPK）模型，并利用这些模型优化治疗肺炎的给药方案。一项前瞻性研究在79名接受静脉注射甲氧苄啶-磺胺甲噁唑治疗的患者中进行。研究采用非线性混合效应模型建立PopPK模型，以评估肝功能、肾功能及基因多态性（和）对药代动力学参数的影响。研究采用蒙特卡洛模拟来确定最佳给药方案。对SMX和TMP的药代动力学分析涵盖了来自79名成年患者的232个给药后血浆浓度数据。一级消除的单室模型最能描述这些数据。肌酐清除率（CrCL）与SMX和TMP的药代动力学参数均显著相关，而连续性肾脏替代治疗仅对SMX模型有显著影响。肝功能、及基因型对模型未显示出统计学上的显著影响。对于CrCL <15 mL/min的患者，每日50 mg/kg的复方新诺明（分三次给药）方案是可行的。然而，对于肾功能正常的患者，指南推荐的每日90 mg/kg剂量存在超治疗窗暴露的风险。本研究为SMX和TMP在患者中的应用提供了关键的药代动力学见解，强调了对肾功能不全患者进行剂量调整的必要性。当前临床指南推荐的给药方案存在药物过度暴露的风险。我们的研究提供了一种更精确的给药策略，以优化治疗效果和安全性。

### 第二部分 AI 大师评价

本研究通过群体药代动力学（PopPK）建模与蒙特卡洛模拟，精准探究了甲氧苄啶-磺胺甲噁唑在真实患者群体中的药代动力学特征。其核心价值在于揭示了肌酐清除率是影响药物暴露的关键因素，并明确指出当前指南推荐剂量可能对肾功能正常患者造成过度暴露风险。这项发现对于临床实践具有重要指导意义，它推动了基于个体肾功能状态的精准化给药方案的制定，从而在保证疗效的同时，最大限度地提升了用药安全性。

---

速递结束，祝您工作愉快！